產品
Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial
Novo Nordisk shares fell after a late-stage trial of ziltivekimab was unable to reduce major adverse cardiovascular events compared with a placebo, a setback for the company's cardiovascular pipeline.
大盤 開啟原文 ↗